Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma ...Middle East

This milestone marks transition of Perfuse Therapeutics to a clinical-stage company SAN FRANCISCO, April 4, 2023 /PRNewswire/ -- Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the US...

Read More Details
Finally We wish PressBee provided you with enough information of ( Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma )

Also on site :

• Numbrix 9 - June 24
• Today's Wordle Hint, Answer for 1466 on Tuesday, June 24, 2025
• NYT Connections Sports Edition Today: Hints and Answers for June 24